Novartis gains rights to two oral targeted investigational therapies focusing on patients with blood disorders and cancers
27-Nov-2009 -
Novartis has gained exclusive rights to two oral targeted investigational therapies for patients with a range of life-threatening blood disorders and cancers that currently do not have effective treatment options. Under a licensing agreement with Incyte Corporation, Novartis will have ...
angiogenesis
blood disorders
clinical trials
+10